AMZ001 for the Treatment of Knee Osteoarthritis Symptoms
Status:
Completed
Trial end date:
2019-07-09
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, 4-week
trial of a formulation of AMZ001 once or twice daily versus placebo twice daily, including a
single-blind treatment group with a commercial gel four times daily.